ArticleCellular and molecular life sciences : CMLS2025
Newly-engineered angiopoietin-1 as a cell-priming agent for CVD.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Human peripheral blood stem cells (PBSC) that have been most frequently used for repair or regeneration in ischemic cardiovascular disease (CVD) showed limitations in their efficacy. We previously reported that angiopoietin-1 (Ang1) is the cell-priming agent to enhance the vasculogenic potential of PBSC. The limitation was the difficulty to produce Ang1 protein with high efficiency. In this study, we engineered Ang1 structure and made FVA3-Ang1 by adding VASP and COMP sequence for stable tetramer formation as well as FLAG sequence for purification in large scale production and a signal peptide derived from influenza A virus (IAV) for better protein expression. FVA3-Ang1 showed stronger effect on endothelial cells than naïve Ang1 or COMP-Ang1 in terms of gene expression of Ang1, Ang2, VEGFA, FGF2, and KDR, as well as phosphorylation of Tie2, ERK, and Akt. Then we primed PBSC with FVA3-Ang1 and examined the transcriptome analysis. Priming for 1 h did not change whole gene expression profiles of PBSC, whereas priming for 24 h did change the pattern from myeloid toward endotheloid lineage. In mouse models of hind-limb ischemia and myocardial infarction, FVA3-Ang1-primed PBSCs showed superior engraftment and tissue regeneration compared to non-primed cells. A clinical trial is underway to assess efficacy and safety of FVA3-Ang1-primed PBSCs when infused via the culprit coronary artery following emergent stent implantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.